These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38010850)

  • 1. A center-based, ambulatory care concept for hidradenitis suppurativa improves patient outcomes and is also cost-effectiveness.
    Heise M; Staubach P; Nikolakis G; Schollenberger L; Mauch M; Burckhardt M; Zamsheva M; Strobel A; Langer G; Bechara F; Kirschner U; Hennig K; Kunte C; Goebeler M; Podda M; Grabbe S; Schultheis M
    J Dermatolog Treat; 2023 Dec; 34(1):2284105. PubMed ID: 38010850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A centre-based ambulatory care concept for hidradenitis suppurativa improves disease activity, disease burden and patient satisfaction: results from the randomized controlled EsmAiL trial.
    Schultheis M; Staubach P; Nikolakis G; Schollenberger L; Mauch M; Burckhardt M; Heise M; Zamsheva M; Strobel A; Langer G; Bechara F; Kirschner U; Hennig K; Kunte C; Goebeler M; Grabbe S
    Br J Dermatol; 2023 Jul; 189(2):170-179. PubMed ID: 37132470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.
    Lovrić I; Brkić J; Ćorluka M; Čović M; Pejić J; Zeljko Penavić J
    Acta Dermatovenerol Croat; 2021 Jul; 29(2):108-110. PubMed ID: 34477078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adalimumab for Treating Moderate-to-Severe Hidradenitis Suppurativa: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Tappenden P; Carroll C; Stevens JW; Rawdin A; Grimm S; Clowes M; Kaltenthaler E; Ingram JR; Collier F; Ghazavi M
    Pharmacoeconomics; 2017 Aug; 35(8):805-815. PubMed ID: 28176188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa.
    Gulliver W; Zouboulis CC; Prens E; Jemec GB; Tzellos T
    Rev Endocr Metab Disord; 2016 Sep; 17(3):343-351. PubMed ID: 26831295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early health economic modelling for a treatment candidate in hidradenitis suppurativa.
    Willems D; Charokopou M; Evers SMAA; Hiligsmann M
    J Med Econ; 2020 Dec; 23(12):1516-1524. PubMed ID: 33084453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of life measurement in hidradenitis suppurativa: position statement of the European Academy of Dermatology and Venereology task forces on Quality of Life and Patient-Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa.
    Chernyshov PV; Zouboulis CC; Tomas-Aragones L; Jemec GB; Svensson A; Manolache L; Tzellos T; Sampogna F; Pustisek N; van der Zee HH; Marron SE; Spillekom-van Koulil S; Bewley A; Linder D; Abeni D; Szepietowski JC; Augustin M; Finlay AY
    J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):1633-1643. PubMed ID: 31037773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study.
    Rivera-Díaz R; Pozo T; Alfageme F; Díaz Ley B; Osorio GF; Chico R; Vilarrasa E; Silvente C; Ciudad Blanco C; Romaní J; Martorell A; Fernández P; Romero Ferreiro C; Molina Leyva A
    Actas Dermosifiliogr; 2023 Oct; 114(9):T755-T762. PubMed ID: 37479135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study.
    Rivera-Díaz R; Pozo T; Alfageme F; Díaz Ley B; Osorio GF; Chico R; Vilarrasa E; Silvente C; Ciudad Blanco C; Romaní J; Martorell A; Fernández P; Romero Ferreiro C; Molina Leyva A
    Actas Dermosifiliogr; 2023 Oct; 114(9):755-762. PubMed ID: 37331620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resource utilization, work productivity and costs in patients with hidradenitis suppurativa: a cost-of-illness study.
    Gáspár K; Hunor Gergely L; Jenei B; Wikonkál N; Kinyó Á; Szegedi A; Remenyik É; Kiss N; Jin X; Sárdy M; Beretzky Z; Péntek M; Gulácsi L; Bánvölgyi A; Brodszky V; Rencz F
    Expert Rev Pharmacoecon Outcomes Res; 2022 Apr; 22(3):399-408. PubMed ID: 33629618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drivers of disease severity and burden of hidradenitis suppurativa: a cross-sectional analysis on 553 German patients.
    Schultheis M; Grabbe S; Staubach P; Hennig K; Mauch M; Burckhardt M; Langer G; Heise M; Zamsheva M; Schollenberger L; Strobel A
    Int J Dermatol; 2024 Feb; 63(2):188-195. PubMed ID: 37919257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased utilization of emergency department and inpatient care by patients with hidradenitis suppurativa.
    Khalsa A; Liu G; Kirby JS
    J Am Acad Dermatol; 2015 Oct; 73(4):609-14. PubMed ID: 26190241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the psychological burden of patients with hidradenitis suppurativa.
    Frings VG; Bauer B; Glöditzsch M; Goebeler M; Presser D
    Eur J Dermatol; 2019 Jun; 29(3):294-301. PubMed ID: 31145081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic analysis of the costs associated with Hidradenitis suppurativa at a German University Hospital.
    Frings VG; Schöffski O; Goebeler M; Presser D
    PLoS One; 2021; 16(8):e0255560. PubMed ID: 34347845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LAight® Therapy Significantly Enhances Treatment Efficacy of 16 Weeks of Topical Clindamycin Solution in Hurley I and II Hidradenitis Suppurativa: Results from Period A of RELIEVE, a Multicenter Randomized, Controlled Trial.
    Schultheis M; Staubach P; Nikolakis G; Grabbe S; Ruckes C; von Stebut E; Kirschner U; Matusiak Ł; Szepietowski JC
    Dermatology; 2022; 238(3):476-486. PubMed ID: 34535610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of hidradenitis suppurativa on professional life.
    Schneider-Burrus S; Kalus S; Fritz B; Wolk K; Gomis-Kleindienst S; Sabat R
    Br J Dermatol; 2023 Jan; 188(1):122-130. PubMed ID: 36689513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world safety and effectiveness of adalimumab in patients with hidradenitis suppurativa: 12-week interim analysis of post-marketing surveillance in Japan.
    Hayashi N; Hayama K; Takahashi K; Kurokawa I; Okazaki M; Kashiwagi T; Iwashita E; Terui T
    J Dermatol; 2022 Apr; 49(4):411-421. PubMed ID: 35040156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Burden of Hidradenitis Suppurativa Signs and Symptoms in Quality of Life: Systematic Review and Meta-Analysis.
    Montero-Vilchez T; Diaz-Calvillo P; Rodriguez-Pozo JA; Cuenca-Barrales C; Martinez-Lopez A; Arias-Santiago S; Molina-Leyva A
    Int J Environ Res Public Health; 2021 Jun; 18(13):. PubMed ID: 34206415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hidradenitis Suppurativa in a Large Cohort of Italian Patients: Evaluation of the Burden of Disease.
    Fabbrocini G; Ruina G; Giovanardi G; Dini V; Raone B; Venturini M; Caposiena Caro RD; Veraldi S; Cannavò SP; Merlo G; Bertoldi AM; Fiorentini F; Molinelli E; Atzori L; Bongiorno MR; Lo Re M; Skroza N; Lasagni C; Franchi C; Ardigò M; Di Costanzo L; Stingeni L; Amerio P; Sanna F; Pescitelli L; Broganelli P; De Cupis C; Gualberti G; Saragaglia V; Argenziano G
    Dermatology; 2022; 238(3):487-497. PubMed ID: 34474409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study.
    Gottlieb A; Menter A; Armstrong A; Ocampo C; Gu Y; Teixeira HD
    J Drugs Dermatol; 2016 Oct; 15(10):1192-1196. PubMed ID: 27741335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.